This is the first time that the FDA has approved a treatment for nr-axSpA. “Today’s approval of Cimzia fulfills an unmet need for patients suffering from non-radiographic axial
Elisabeth Björk, Senior Vice President, Head of late Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals, said: “This approval of Forxiga in Japan means that people with type-1 diabetes whose
The multimillion-pound drug discovery alliance will bring together Cancer Research UK’s network of scientists and drug discovery expertise, LifeArc’s therapeutic antibody engineering and development expertise and Ono’s expertise
Mayzent is claimed to the first oral drug to treat secondary progressive MS with active disease. Mayzent is approved across the MS spectrum for clinically isolated syndrome (CIS),
This approval marks the first country approval in the world for SKYRIZI. “With this first global approval of SKYRIZI, we are excited to bring a new treatment option
This is the first approval of Forxiga for the treatment of patients with T1D. Elisabeth Björk, Senior Vice President, Head of late Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals,
The companies have reached settlement more than five years after the litigation started with Xarelto. During the period, all six cases related to Xarelto went to trial. Bayer
“Today’s submission brings us one step closer to our goal of improving treatment outcomes for people newly diagnosed with multiple myeloma,” said José Antonio Burón Vidal, VP Medical
Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.
The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72. “Although emricasan did not have the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.